This video explores the evolving role of biomarkers in kidney cancer treatment, especially as more therapies become available for both metastatic and adjuvant settings. Key questions include which…
Medicosis Perfectionalis dives into renal cell carcinoma (RCC), a type of kidney cancer. The tutorial covers RCC’s origins in proximal renal tubular cells, the most common subtype (clear…
Toni K. Choueiri, MD, director of the Lank Center for Genitourinary Oncology, director of the Kidney Cancer Center, senior physician at Dana-Farber Cancer Institute, and Jerome and Nancy…
Yousef Zakharia, MD, clinical associate professor of internal medicine at the University of Iowa Holden Comprehensive Cancer Center, discusses completing a recent phase 1 trial studying seleno-L-methionine (SLM)…
Elizabeth R. Plimack, MD, MS, chief of the Division of Genitourinary Medical Oncology, director of Genitourinary Clinical Research, and professor in the Department of Hematology/Oncology at Fox Chase…
Bradley McGregor, MD, clinical director at Lank Center for Genitourinary Oncology, senior physician at Dana-Farber Cancer Institute, and instructor of medicine at Harvard Medical School, discusses a new…
Daniel George, MD, questions whether debulking nephrectomy is still necessary in the age of targeted therapies. In a one-sided non-inferiority study, sunitinib alone was compared to nephrectomy. The…
Studies of pembrolizumab have shown promising antitumor activity across a wide cohort of patients with clear cell renal cell carcinoma (ccRCC). The results of a recent study, named…
According to findings in an extended follow-up of the ongoing CheckMate 214 trial, nivolumab plus ipilimumab is more effective than sunitinib as first-line treatment for patients with advanced…
A treatment is undergoing development in hopes to receive FDA clearance to be the first drug targeted at the third- and fourth-line space in patients with refractory renal cell carcinoma…
A study published in Clinical Cancer Research, authored by James Brugarolas, MD, PhD, professor of internal medicine (hematology/oncology) and director of the Kidney Cancer Program at UT Southwestern, demonstrated…
A study composed of patients from across the USA and Europe observed improved outcomes in those treated with both ilixadencel and sunitinib compared with sunitinib alone. here.
